Page last updated: 2024-09-03

imatinib mesylate and Wilms Tumor

imatinib mesylate has been researched along with Wilms Tumor in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aizawa, Y; Furukawa, T; Fuse, I; Kawakami, M; Kitajima, T; Kurasaki, T; Masuko, M; Narita, M; Oka, Y; Saitoh, A; Sugiyama, H; Takahashi, M; Takenouchi, S; Toba, K; Watanabe, N	1

Other Studies

1 other study(ies) available for imatinib mesylate and Wilms Tumor

Article	Year
WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. International journal of medical sciences, 2010, Apr-20, Volume: 7, Issue:2 Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; Vaccination; Wilms Tumor; WT1 Proteins	2010

Article

Year

WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase.

International journal of medical sciences, 2010, Apr-20, Volume: 7, Issue:2

Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; Vaccination; Wilms Tumor; WT1 Proteins

2010